PE133699A1 - Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica - Google Patents
Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolicaInfo
- Publication number
- PE133699A1 PE133699A1 PE1998001146A PE00114698A PE133699A1 PE 133699 A1 PE133699 A1 PE 133699A1 PE 1998001146 A PE1998001146 A PE 1998001146A PE 00114698 A PE00114698 A PE 00114698A PE 133699 A1 PE133699 A1 PE 133699A1
- Authority
- PE
- Peru
- Prior art keywords
- antiviral
- methyl
- cyan
- halo
- benzimidazole
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 abstract 8
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 6
- -1 ISOPROPYL Chemical class 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000000510 mucolytic effect Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6676797P | 1997-11-24 | 1997-11-24 | |
| US6670097P | 1997-11-25 | 1997-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE133699A1 true PE133699A1 (es) | 2000-03-05 |
Family
ID=26747058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001146A PE133699A1 (es) | 1997-11-24 | 1998-11-25 | Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica |
Country Status (23)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4172541B2 (ja) | 2001-04-09 | 2008-10-29 | ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド | グアニジノ化合物 |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| FR2842422B1 (fr) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
| RU2225401C1 (ru) * | 2002-09-16 | 2004-03-10 | Катаев Валерий Алексеевич | 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность |
| US20040167194A1 (en) | 2003-02-20 | 2004-08-26 | Randall Jared Lynn | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form |
| US7268255B2 (en) * | 2003-02-20 | 2007-09-11 | Lonza Ag | Process for the preparation of N-substituted formamides |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| WO2005115395A2 (en) * | 2004-05-25 | 2005-12-08 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| EP1956906A4 (en) | 2005-11-09 | 2009-12-30 | Combinatorx Inc | METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES |
| RU2306137C1 (ru) * | 2005-12-28 | 2007-09-20 | Денис Вячеславович Лисицын | Средство для профилактики и лечения гриппа |
| WO2013130577A2 (en) * | 2012-02-27 | 2013-09-06 | Eye Therapies, Llc | Compositions and methods for the treatment of migraine |
| US20150133516A1 (en) * | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
| KR20180105129A (ko) * | 2015-11-30 | 2018-09-27 | 노부스 테라퓨틱스, 인크. | 이과학적 예방 및 치료를 위한 조성물 및 방법 |
| EA030197B1 (ru) * | 2016-03-22 | 2018-07-31 | Общество С Ограниченной Ответственностью "Рубикон" | Таблетированная форма противовирусного лекарственного средства |
| JP7163014B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 感冒薬 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| US4036976A (en) | 1973-04-05 | 1977-07-19 | Sandoz, Inc. | Substituted imidazolinylamino-indazoles |
| US4217356A (en) | 1975-08-22 | 1980-08-12 | Sandoz Ltd. | 2-Imidazolinylamino-2,1,3-benzothiadiazoles |
| US4398028A (en) | 1977-01-14 | 1983-08-09 | Sandoz Ltd. | Bicyclic heterocyclic amino derivatives |
| EP0086428B1 (en) | 1979-08-23 | 1987-07-29 | Beecham Group Plc | Antidiarrhoea veterinary composition, its production and oral doser containing it |
| JPS57501378A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1980-09-05 | 1982-08-05 | ||
| FR2638356A1 (fr) | 1988-10-28 | 1990-05-04 | Anben | Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome |
| US5180721A (en) | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5281591A (en) | 1989-05-22 | 1994-01-25 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5231096A (en) | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| TW300219B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
| US5478858A (en) | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| ID24081A (id) * | 1997-04-15 | 2000-07-06 | Procter & Gamble | Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor |
-
1998
- 1998-11-20 JP JP2000522100A patent/JP2001524478A/ja not_active Withdrawn
- 1998-11-20 PL PL98340711A patent/PL340711A1/xx unknown
- 1998-11-20 CA CA002311344A patent/CA2311344C/en not_active Expired - Fee Related
- 1998-11-20 DE DE69825075T patent/DE69825075T2/de not_active Expired - Lifetime
- 1998-11-20 AT AT98959512T patent/ATE271048T1/de not_active IP Right Cessation
- 1998-11-20 TR TR2000/02242T patent/TR200002242T2/xx unknown
- 1998-11-20 BR BR9815017-0A patent/BR9815017A/pt not_active IP Right Cessation
- 1998-11-20 CN CN98813286A patent/CN1284073A/zh active Pending
- 1998-11-20 SK SK779-2000A patent/SK7792000A3/sk unknown
- 1998-11-20 HU HU0101469A patent/HUP0101469A3/hu unknown
- 1998-11-20 IL IL13630398A patent/IL136303A/en not_active IP Right Cessation
- 1998-11-20 EP EP98959512A patent/EP1037887B1/en not_active Expired - Lifetime
- 1998-11-20 ES ES98959512T patent/ES2223143T3/es not_active Expired - Lifetime
- 1998-11-20 US US09/554,698 patent/US6486190B1/en not_active Expired - Lifetime
- 1998-11-20 RU RU2000116269/04A patent/RU2193562C2/ru not_active IP Right Cessation
- 1998-11-20 KR KR1020007005675A patent/KR20010032435A/ko not_active Abandoned
- 1998-11-20 WO PCT/US1998/024694 patent/WO1999026942A1/en not_active Application Discontinuation
- 1998-11-20 NZ NZ504707A patent/NZ504707A/xx unknown
- 1998-11-25 PE PE1998001146A patent/PE133699A1/es not_active Application Discontinuation
- 1998-11-25 CO CO98069637A patent/CO4970802A1/es unknown
- 1998-11-26 IN IN3539DE1998 patent/IN190809B/en unknown
-
1999
- 1999-02-10 TW TW087119586A patent/TW505642B/zh active
-
2000
- 2000-05-24 NO NO20002655A patent/NO20002655L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002655L (no) | 2000-07-24 |
| DE69825075T2 (de) | 2005-08-25 |
| ES2223143T3 (es) | 2005-02-16 |
| TR200002242T2 (tr) | 2000-11-21 |
| CA2311344A1 (en) | 1999-06-03 |
| CO4970802A1 (es) | 2000-11-07 |
| CA2311344C (en) | 2006-02-07 |
| EP1037887B1 (en) | 2004-07-14 |
| EP1037887A1 (en) | 2000-09-27 |
| KR20010032435A (ko) | 2001-04-25 |
| BR9815017A (pt) | 2001-09-11 |
| SK7792000A3 (en) | 2001-01-18 |
| ATE271048T1 (de) | 2004-07-15 |
| IN190809B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2003-08-23 |
| PL340711A1 (en) | 2001-02-26 |
| RU2193562C2 (ru) | 2002-11-27 |
| NZ504707A (en) | 2002-11-26 |
| CN1284073A (zh) | 2001-02-14 |
| IL136303A (en) | 2004-02-08 |
| US6486190B1 (en) | 2002-11-26 |
| HUP0101469A3 (en) | 2003-01-28 |
| JP2001524478A (ja) | 2001-12-04 |
| NO20002655D0 (no) | 2000-05-24 |
| TW505642B (en) | 2002-10-11 |
| WO1999026942A8 (en) | 2000-08-03 |
| IL136303A0 (en) | 2001-05-20 |
| HUP0101469A2 (hu) | 2001-10-28 |
| WO1999026942A1 (en) | 1999-06-03 |
| DE69825075D1 (de) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE133699A1 (es) | Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica | |
| BR0208626A (pt) | Composição antifúngica com biodisponibilidade intensificada | |
| BR9408343A (pt) | Derivados 5-(2-imidazolinil amino) benzimidazol sua preparação e seu uso como agonistas alfa-2 adrenoceptor | |
| PE20050145A1 (es) | Dihidroquinazolinas sustituidas como agentes antivirales | |
| HN2003000009A (es) | Encapsulamiento por recubrimiento con una mezcla de lipidos y compuestos hidrofobicos de alto punto de fusion. | |
| DK1654002T4 (da) | Sammensætninger til fremføring af terapeutiske midler til øjnene | |
| ES2536918T3 (es) | Compuestos de benzoilpirazol y herbicidas que los contienen | |
| AR017122A1 (es) | DERIVADOS DE BENZAMIDOXIMA, BENZONITRILOS Y COMPUESTOS DE BENZAMIDOXIMAS INTERMEDIARIOS EN LA SíNTESIS DE DICHOS DERIVADOS, LA UTILIZACIoN DE LOS MISMOS PARA CONTROLAR HONGOS DANINOS, LAS COMPOSICIONES FUNGUICIDAS QUE LOS CONTIENEN Y EL MÉTODO PARA CONTROLAR HONGOS DANINOS CON DICHOS DERIVADOS O SUS | |
| CO6270288A2 (es) | Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| PE20040608A1 (es) | Compuestos de alquino con efecto antagonico de la hcm y medicamentos que los contienen | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| CO5021135A1 (es) | Compuestos quimicos | |
| AR038379A1 (es) | Esteres de acidos fluoreno-carboxilicos, procedimientos para su preparacion asi como su utilizacion en calidad de medicamentos | |
| DE69326610D1 (de) | Arzneimittel gegen glaukom | |
| ES2523873T3 (es) | Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes | |
| PE16399A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores | |
| AR012426A1 (es) | Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida. | |
| PE20080840A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
| PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
| PE20070850A1 (es) | Amidas inhibidoras de leucotrieno a4 hidrolasa | |
| PE20040682A1 (es) | Derivados de ciclobutano como antagonistas de nk1 | |
| PE20050021A1 (es) | Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida | |
| PE20030707A1 (es) | Agonistas muscarinicos | |
| PE20050350A1 (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobencenos sustituidos como agonistas de 5-ht1f |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |